Maheswara Satya Golla, MD
Interventional Cardiology · Brighton, MANPI 1154761716
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,259 of the $8,497 with a category attached, or 61.9%. Abbott accounts for 65.2% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $5,763, 4.9 times the $1,177 reported in 2019.
Across 80 payments — averaging $106.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Boston Scientific$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$398
- Shockwave Medical, Inc$366
- Medtronic$197
- E.r. Squibb & Sons, L.L.C.$149
- plus $706 from 11 others
What the payments were for
- Travel & lodging$5,25962%
- Food & beverage$3,23938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $5,540 |
| Boston Scientific | 9 | $1,141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $398 |
| Shockwave Medical, Inc | 3 | $366 |
| Medtronic(2 entities) | 2 | $197 |
| E.r. Squibb & Sons, L.L.C. | 6 | $149 |
| Livanova USA, Inc. | 1 | $143 |
| Abiomed | 1 | $129 |
| Novartis | 5 | $86 |
| ZOLL Circulation Inc | 1 | $85 |
| Amarin Pharma, Inc. | 4 | $69 |
| Angiodynamics, Inc. | 2 | $64 |
| Merck | 3 | $54 |
| AstraZeneca | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Johnson & Johnson | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,497 in reported general payments places this provider in the 60th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $29,706 |
| Metoprolol Succinate | 45 | $692 |
| ClopidogrelClopidogrel Bisulfate | 25 | $289 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 26 | $255 |
| Atorvastatin Calcium | 29 | $241 |
| Losartan Potassium | 17 | $182 |
| Amlodipine Besylate | 32 | $150 |
| Lisinopril | 24 | $141 |
| Chlorthalidone | 14 | $139 |
| Carvedilol | 19 | $132 |
| Furosemide | 26 | $129 |
| Metoprolol Tartrate | 19 | $86 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Brighton
- Lawrence GarciaBrighton$85K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Thomas PiemonteBurlington$330K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.